Evidence map›Paper›PMID 33845766›Full record

SynthesisBMC infectious diseases2021

Informing the public health response to COVID-19: a systematic review of risk factors for disease, severity, and mortality.

M Flook, C Jackson, E Vasileiou, C R Simpson, M D Muckian, U Agrawal, C McCowan, Y Jia, J L K Murray, L D Ritchie and 6 more

Abstract readSystematic Review
In one paragraph

Synthesis in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Surveillance of SARS-CoV-2 variants in Henan, China from 2023 to 2024.Frontiers in cellular and infection microbiology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

M FlookUsher Institute, University of Edinburgh, 30 West Richmond Street, Edinburgh, EH8 9DX, UK.
C JacksonMedical Research Council Clinical Trials Unit, University College London, London, UK.
E VasileiouUsher Institute, University of Edinburgh, 30 West Richmond Street, Edinburgh, EH8 9DX, UK.
C R SimpsonUsher Institute, University of Edinburgh, 30 West Richmond Street, Edinburgh, EH8 9DX, UK.
M D MuckianUsher Institute, University of Edinburgh, 30 West Richmond Street, Edinburgh, EH8 9DX, UK.
U Agrawal *School of Medicine, University of St. Andrews, St. Andrews, UK.
C McCowan *School of Medicine, University of St. Andrews, St. Andrews, UK.
Y Jia *Freelance consultant, Beijing, People's Republic of China.
J L K Murray *National Health Service Fife, Kirkcaldy, UK.
L D Ritchie *School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK.
C Robertson *Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK.
S J Stock *Usher Institute, University of Edinburgh, 30 West Richmond Street, Edinburgh, EH8 9DX, UK.
X Wang *Usher Institute, University of Edinburgh, 30 West Richmond Street, Edinburgh, EH8 9DX, UK.
M E J Woolhouse *Usher Institute, University of Edinburgh, 30 West Richmond Street, Edinburgh, EH8 9DX, UK.
A SheikhUsher Institute, University of Edinburgh, 30 West Richmond Street, Edinburgh, EH8 9DX, UK.
H R StaggUsher Institute, University of Edinburgh, 30 West Richmond Street, Edinburgh, EH8 9DX, UK. helen.stagg@ed.ac.uk.ORCID http://orcid.org/0000-0003-4022-3447

Funding

Department of Health 11/46/23Medical Research Council MC_PC_19075Medical Research Council MC_UU_12023/26Medical Research Council MR/R008345/1Wellcome TrustWellcome Trust WT 209560/Z/17/Z
6 · The paper itself

Abstract

backgroundSevere Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) has challenged public health agencies globally. In order to effectively target government responses, it is critical to identify the individuals most at risk of coronavirus disease-19 (COVID-19), developing severe clinical signs, and mortality. We undertook a systematic review of the literature to present the current status of scientific knowledge in these areas and describe the need for unified global approaches, moving forwards, as well as lessons learnt for future pandemics.

methodsMedline, Embase and Global Health were searched to the end of April 2020, as well as the Web of Science. Search terms were specific to the SARS-CoV-2 virus and COVID-19. Comparative studies of risk factors from any setting, population group and in any language were included. Titles, abstracts and full texts were screened by two reviewers and extracted in duplicate into a standardised form. Data were extracted on risk factors for COVID-19 disease, severe disease, or death and were narratively and descriptively synthesised.

resultsOne thousand two hundred and thirty-eight papers were identified post-deduplication. Thirty-three met our inclusion criteria, of which 26 were from China. Six assessed the risk of contracting the disease, 20 the risk of having severe disease and ten the risk of dying. Age, gender and co-morbidities were commonly assessed as risk factors. The weight of evidence showed increasing age to be associated with severe disease and mortality, and general comorbidities with mortality. Only seven studies presented multivariable analyses and power was generally limited. A wide range of definitions were used for disease severity.

conclusionsThe volume of literature generated in the short time since the appearance of SARS-CoV-2 has been considerable. Many studies have sought to document the risk factors for COVID-19 disease, disease severity and mortality; age was the only risk factor based on robust studies and with a consistent body of evidence. Mechanistic studies are required to understand why age is such an important risk factor. At the start of pandemics, large, standardised, studies that use multivariable analyses are urgently needed so that the populations most at risk can be rapidly protected. REGISTRATION: This review was registered on PROSPERO as CRD42020177714 .

Indexed as

Risk FactorsChinaCOVID-19HumansPandemicsPublic HealthCoronavirusCOVID-19MorbidityMortalityReviewRisk factorsSystematic review

Identifiers

PMID33845766
PMCPMC8040367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.